was reported that the World Health Organization (WHO) issued some significant and long overdue recommendations on cannabis. These recommendations have not been officially published, but we expect it to happen soon. If the recommendations are adopted in the United Nations (UN) wholesale trade, they will have a significant impact on the control of cannabis and its components worldwide
It is important to note that WHO does not recommend the legalization of marijuana. Therefore, no one should wait for the doors to move widely over the international cannabis trade . However, WHO development is welcome news almost 60 years after the unlawful ban on cannabis under international law.
WHO recommendations are presented as follows:
Remove the entire plant from marijuana and cannabis resin from the 1961 Single Convention on Narcotic Drugs (hereafter referred to as & # 39; Single Convention & # 39; relatively safe, and drugs under schedule IV are the most controlled.)
Put cannabis extracts and tinctures containing delta-9-tetrahydrocannabinol (THC) in List III of the Single Convention.
Remove THC and its isomers completely from the 1972 Protocol to the Single Convention. (The 1972 Protocol is a follow-up agreement requiring states to effectively implement books on cannabis cultivation.)
Find out that cannabidiol and CBD-focused preparations containing up to 0.2 percent THC are not subject to international control at all.
So what would all this mean? First, cannabis containing more than minor amounts of THC is still under control. The whole plant of marijuana would no longer be in the same drug class as heroin and fentanyl, but it would not be eligible for trading in the same way as coffee or even tobacco. Secondly, THC's fortified preparations would be more strictly controlled than flower, but not drachonian levels. Thirdly, the penalties for distributing and holding cannabis in any form will be significantly reduced. Fourth, CBD would be treated as bonons. All in all, the WHO approach is measured and the scientific endeavor is to isolate and distinguish the effects of different parts and preparations of the plant.
WHO's assessment of CBD could directly affect the impact on US legislation. Readers of this blog can remember that the US Drug Control Agency (DEA) has taken position according to which the United States is "unable to maintain [Single Convention] obligations if CBD were under CSA control "The Food and Drug Administration (FDA) ultimately dropped according to DEA's interpretation of Epidiolex (approved CBD medicine), and recently issued a statement warning that it It is illegal to introduce foods containing added CBD … into transnational trading. ”
If the UN accepts the WHO recommendation, however, the FDA can quickly translate the course. When the FDA agreed to schedule Epidiolex, it recommended: “If the contractual obligations do not require CBD control, or CBD's international control measures are lifted for some time, the CSA's list recommendation should be reviewed without delay. “Supposedly, state health authorities would be in line with the FDA decision, and we would end things like last week's attacks in New York and Maine.
At some point this year, it is likely that the UN will vote on the WHO recommendations on cannabis restructuring. A really, really interesting question is where the United States has contributed a lot to that important day. The US has always been an international hard line for cannabis, although most of its states have legalized marijuana for medical or recreational use. Nowadays things are changing rapidly – both at home and globally.
For more information on cannabis and international law, see